Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages
Abd El-Tawab, A., El-Hofy, F., Nasr, E., Sriranganathan, N., Soliman, E. (2016). Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages. EKB Journal Management System, 31(1), 124-131. doi: 10.21608/bvmj.2016.31237
Ashraf A. Abd El-Tawab; Fatma I. El-Hofy; Essam A. Nasr; Nammalwar Sriranganathan; Enas A. Soliman. "Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages". EKB Journal Management System, 31, 1, 2016, 124-131. doi: 10.21608/bvmj.2016.31237
Abd El-Tawab, A., El-Hofy, F., Nasr, E., Sriranganathan, N., Soliman, E. (2016). 'Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages', EKB Journal Management System, 31(1), pp. 124-131. doi: 10.21608/bvmj.2016.31237
Abd El-Tawab, A., El-Hofy, F., Nasr, E., Sriranganathan, N., Soliman, E. Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages. EKB Journal Management System, 2016; 31(1): 124-131. doi: 10.21608/bvmj.2016.31237

Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Benha Veterinary Medical Journal
Article 20, Volume 31, Issue 1, September 2016, Page 124-131  XML PDF (395.38 K)
Document Type: Original Article
DOI: 10.21608/bvmj.2016.31237
View on SCiNiTO View on SCiNiTO
Authors
Ashraf A. Abd El-Tawab1; Fatma I. El-Hofy1; Essam A. Nasr2; Nammalwar Sriranganathan3; Enas A. Soliman1
1Department of Bacteriology, Immunology and Mycology Fac. Vet. Med. Benha University, Egypt
2Department of diagnostic bacteriology. Veterinary serums and vaccines research Institute, Abbasia, Cairo, Egypt
3Department of Biomedical Sciences & Pathobiology Virginia-Maryland College of Veterinary Medicine, USA
Abstract
Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonary
and meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has been
restricted to immune-deficient individuals since 2007 because of its combined complications. Which treated with
antituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed more
susceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycin
than BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between the
two tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitory
activity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin>
capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin =
streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publications
describe the activity of antituberculosis drugs against intracellular growing BCG strains
Keywords
M. bovis BCG – anti-tuberculosis drugs; macrophages
Statistics
Article View: 96
PDF Download: 229